178445-89-1

Basic information

• Product Name: (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol
• Synonyms: (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol
• CAS NO: 178445-89-1
• Molecular Weight: 402.488
• Mol File: 178445-89-1.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol(178445-89-1)
• EPA Substance Registry System: (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol(178445-89-1)

Safety Data

• Hazardous Substances Data: 178445-89-1(Hazardous Substances Data)

Usage

Description

(R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is a chiral molecule with a complex structure, consisting of a phenyl group with a tert-butoxycarbonylmethoxy substituent, a 3,4-dimethoxyphenyl group, and a propan-1-ol functional group. The presence of a chiral center indicates that this molecule has two enantiomeric forms, denoted as (R) and (S). Its intricate structure suggests potential applications in various fields such as medicinal chemistry, material science, or organic synthesis. Further research and testing are required to determine its specific properties and potential uses.

Uses

Used in Medicinal Chemistry:
(R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is used as a chiral molecule for its potential application in the development of new drugs. (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol's unique structure may allow it to interact with biological targets in novel ways, leading to the discovery of new therapeutic agents.
Used in Material Science:
In the field of material science, (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is used as a building block for the synthesis of new materials with specific properties. Its chiral nature and complex structure may contribute to the creation of materials with unique optical, electronic, or mechanical characteristics.
Used in Organic Synthesis:
(R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is used as an intermediate in organic synthesis for the production of other complex molecules. Its chiral center and diverse functional groups make it a valuable starting material for the synthesis of various organic compounds with potential applications in different industries.
Used in Pharmaceutical Industry:
(R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is used as a key component in the development of new pharmaceuticals. Its unique structure may offer novel mechanisms of action or improved pharmacokinetic properties, leading to more effective treatments for various diseases.
Used in Chemical Research:
In the field of chemical research, (R)-1-(3-(tert-butoxycarbonylmethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propan-1-ol is used as a model compound for studying the effects of chirality on molecular interactions and reactivity. This research may provide valuable insights into the design of new chiral molecules with specific properties and applications.

Upstream product

• 178445-86-8 2[[3-(3,4-dimethyoxyphenyl)-1-oxopropyl]phenoxy]acetic acid 1,1-dimethylester 
• 178445-83-5 3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)-1-propanone 
• 178445-80-2 (E)-1-(3,4-dimethoxyphenyl)-3-(3-hydroxyphenyl)prop-2-en-1-one 
• 121-71-1 3-Hydroxyacetophenone 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 215168-57-3 3,4-dimethoxy-3’-hydroxychalcone 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 111-42-2 2,2'-iminobis[ethanol] 

Downstream Products

• 178446-55-4 (1R)-1-[3-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl-3-(3,4-dimethoxyphenyl)-1-propanyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-piperidinecarboxylate 
• 215169-00-9 2-{3-[(1R)-3-(3,4-dimethoxyphenyl)-1-hydroxypropyl]phenoxy}acetic acid 
• 195202-26-7 (R)-1-(3-(2-(tert-butoxy)-2-oxoethoxy)phenyl)-3-(3,4-dimethoxyphenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate 
• 1373829-44-7 2-(3-((R)-1-(((S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid 
• 178446-02-1 2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid 
• 195202-03-0 (S)-((R)-1-(3-(2-tert-butoxy-2-oxoethoxy)phenyl)-3-(3,4-dimethoxyphenyl)-propyl) piperidine-2-carboxylate 
• 1374119-23-9 2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-((S)-1-(2-((1S,2R)-1-hydroxy-2-methyl cyclohexyl)-2-oxoacetyl)piperidine-2-carbonyloxy)propyl)phenoxy)acetic acid 
• 1374119-24-0 2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-((S)-1-(2-((1R,2S)-1-hydroxy-2-methyl cyclohexyl)-2-oxoacetyl)piperidine-2-carbonyloxy)propyl)phenoxy)acetic acid 

Relevant articles and documents

NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure provides neuroprotective compounds along with their use in treating disease such as Parkinson's disease (PD). The compounds can be used as inhibitors for Parthanatos Associated AIF (apoptosis-inducing factor) Nuclease (PAAN), also known as macrophage migration inhibitor factor (MIF).

Design and Combinatorial Development of Shield-1 Peptide Mimetics Binding to Destabilized FKBP12

On the basis of computational design, a focused one-bead one-compound library has been prepared on microparticle-encoded PEGA1900 beads consisting of small tripeptides with a triazole-capped N-terminal. The library was screened towards a double

Synthetic process of homodimer of FKBP ligand

The invention discloses a synthesis process of homodimer of FKBP ligand and belongs to an improved synthesis process of AP1903, wherein the homodimer of FKBP ligand refers to AP1903. According to theoptimized route of the synthesis process chooses, (S)-piperidine-2-methyl formate is connected to the compound Cpd9' as selected, an acid Cpd6' obtained after ester hydrolysis is easier to be purified by post-treatment purification, and precipitation or extraction treatment can be chosen by the post-treatment purification. Although the total reaction steps of the synthetic route in the prior literature are the same as the optimized route of the invention, the synthetic route in the prior literature belongs to the vertical route, and the post-treatment of the fifth, sixth and eighth steps requires column chromatography, thereby leading to a higher research and development cost. The optimized AP1903 synthetic route belongs to the parallel route, and the post-treatment is simpler and more advantageous for separation and purification, so that the cost of research and development is relatively low and the economic benefit is obviously superior to that of the synthetic route in the prior art.